Co-relation of SARS-CoV-2 related 30-d mortality with HRCT score and RT-PCR Ct value-based viral load in patients with solid malignancy

Table 1 Patient demographic, clinical, baseline laboratory parameter and tumour characteristics, n (%)

Characteristics	Analysable population (n = 123)
Age, yr
Median	59
Range	19-82
< 65	91 (74)
65-74	25 (20.3)
≥ 75	7 (5.7)
Sex
Male	59 (48)
Female	64 (52)
Smoking status
Never smoked	69 (58.9)
Smoker (former/current)	31 (26.3)
Unknown	18 (15.2)
Obesity status
Not specified	106 (86.2)
Obese	13 (10.4)
Data missing	4 (3.4)
Number of comorbidities
0	54 (43.9)
1	32 (26)
≥ 2	37 (30.1)
Type of malignancy
Thorax	10 (8.1)
GIT	9 (7.3)
HPB	40 (32.5)
GUT	49 (39.8)
Others	15 (12.2)
Cancer status
Remission or no evidence of disease	8 (6.5)
Present, stable, or responding to treatment	66 (53.7)
Present, progressive disease unknown	49 (39.8)
ECOG performance status
0 or 1	90 (73.2)
2	18 (14.6)
≥ 3	15 (12.2)
Type of anticancer therapy
None in the 4 wk before COVID-19 diagnosis	14 (11.4)
Non-cytotoxic therapy targeted therapy/endocrine therapy	9 (7.3)
Immunotherapy	3 (2.4)
Cytotoxic systemic therapy	90 (73.2)
External beam radiotherapy	7 (5.7)
Recent surgery
None in the 4 wk before COVID-19 diagnosis	113 (91.9)
Yes	10 (8.9)
Baseline laboratory parameters
C Reactive protein	44 (35.8)
D-Dimer	11 (8.9)
IL-6	5 (4.1)
RT-PCR test (viral load)
Mild (17-24)	49 (39.8)
Moderate (25-31)	30 (24.4)
High (> 31)	44 (35.8)
HRCT score
Mild	77 (62.6)
Moderate	38 (30.8)
Severe	8 (6.5)
Treatment of COVID-19
Hydroxychloroquine (HCQ) alone, azithromycin alone or with combination HCQ/azithromycin/ivermectin	22 (17.9)
+ Steroids	36 (293)
+ Remdesivir	29 (23.6)
+ Tocilizumab	3 (2.4)
+ Plasma therapy	11 (8.9)
Neither	22 (17.9)

GIT: Gastrointestinal tract; HPB: Hepatopancreatobiliary; GUT: Genitourinary tract; COVID-19: Coronavirus disease 2019; ECOG: Eastern Cooperative Oncology Group.